- Home
- LFST vs MLTX Comparison
LFST vs MLTX Comparison
Compare LFST & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- MLTX
- Stock Information
- Founded
- LFST 2015
- MLTX 2021
- Country
- LFST United States
- MLTX Switzerland
- Employees
- LFST N/A
- MLTX N/A
- Industry
- LFST Medical/Nursing Services
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- MLTX Health Care
- Exchange
- LFST Nasdaq
- MLTX Nasdaq
- Market Cap
- LFST 1.9B
- MLTX 2.8B
- IPO Year
- LFST 2021
- MLTX N/A
- Fundamental
- Price
- LFST $5.17
- MLTX $47.55
- Analyst Decision
- LFST Strong Buy
- MLTX Strong Buy
- Analyst Count
- LFST 5
- MLTX 8
- Target Price
- LFST $8.50
- MLTX $77.71
- AVG Volume (30 Days)
- LFST 2.1M
- MLTX 752.7K
- Earning Date
- LFST 08-07-2025
- MLTX 08-06-2025
- Dividend Yield
- LFST N/A
- MLTX N/A
- EPS Growth
- LFST N/A
- MLTX N/A
- EPS
- LFST N/A
- MLTX N/A
- Revenue
- LFST $1,283,503,000.00
- MLTX N/A
- Revenue This Year
- LFST $15.27
- MLTX $103.42
- Revenue Next Year
- LFST $13.94
- MLTX N/A
- P/E Ratio
- LFST N/A
- MLTX N/A
- Revenue Growth
- LFST 16.31
- MLTX N/A
- 52 Week Low
- LFST $4.76
- MLTX $31.42
- 52 Week High
- LFST $8.61
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- LFST 38.55
- MLTX 60.27
- Support Level
- LFST $4.76
- MLTX $42.22
- Resistance Level
- LFST $5.26
- MLTX $48.72
- Average True Range (ATR)
- LFST 0.19
- MLTX 1.60
- MACD
- LFST 0.02
- MLTX 0.09
- Stochastic Oscillator
- LFST 33.34
- MLTX 70.15
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.